Brand name: PHOLENVA (Lenvatinib) 4mg
Generic Name: Lenvatinib
1. Unresectable, locally advanced or metastatic symptomatic or progressive medullary thyroid cancer
2. Can be used with everolimus to treat renal cell carcinoma (RCC, a cancer that starts in the kidneys) in people who have been previously treated with another chemotherapy drug.
3. For inoperable hepatocellular carcinoma (HCC; a type of liver cancer)
4. For patients with local recurrence/metastasis and progression of radioactive iodine-refractory differentiated thyroid cancer
5. In combination with pembrolizumab (the PD-1 inhibitor pembrolizumab) to treat a certain type of endometrial cancer (endometrial cancer) that has spread to other parts of the body, or after chemotherapy drugs Worsening during or after treatment, or not treatable with surgery or radiation therapy.
6. The first pharmacy in India collects and sorts inmedf.com reprint please keep it
1. Thyroid cancer (DTC): 24 mg per day, orally, once a day;
2. Renal cell carcinoma (RCC): 18mg lenvatinib + 5mg everolimus, orally, once a day;
3. Hepatocellular carcinoma (HCC): body weight ≥60kg, 12mg, once a day; body weight <60kg, 8mg, once a day.
Lenvatinib must be taken at the same time each day. If you forget to take a dose and fail to take it within 12 hours, skip the dose and take the next dose at the scheduled time.
Lenvatinib capsules should be swallowed whole or taken by dissolving the capsules in a small glass of liquid. Measure a tablespoon of water or apple juice into a glass and place the capsule (the capsule does not need to be opened or crushed). Leave the capsules in the liquid for at least 10 minutes, stir for at least 3 minutes, and drink the liquid. After drinking, add an equal amount (a tablespoon) of water or apple juice to the glass, mix well and drink the remaining liquid.
This product is contraindicated in patients with known hypersensitivity to lenvatinib or any excipients.
- Adverse reactions
In DTC, the most common adverse reactions (incidence greater than or equal to 30%) for LENVIMA were hypertension, fatigue, diarrhea, arthralgia, myalgia, decreased appetite, decreased weight, nausea, stomatitis, headache, vomiting, proteinuria , Palmoplantar erythrodysesthesia syndrome, abdominal pain, dysphonia.
In renal cancer, the most common adverse reactions (greater than 30%) for LENVIMA + everolimus were diarrhea, fatigue, arthralgia, myalgia, loss of appetite, vomiting, nausea, stomatitis, oral inflammation, hypertension, peripheral edema, Cough, abdominal pain, decreased dyspnea, rash, significant weight loss, bleeding episodes, proteinuria.